BINARY GENOMICS, INC.

Biotech · Private

Circulating tumor DNA (ctDNA) assay based on epigenetic features for monitoring immunotherapy response

Grants
$2.4M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA$398,040
Federal grantDepartment of Health and Human Services · Phase II · Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA$990,771
Federal grantDepartment of Health and Human Services · Phase II · Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA$1,009,228
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1283IMMUNE MODULATORY THERAPIES, LLC——
1284XLOCK BIOSCIENCES, LLC——
1285GENETIC INTELLIGENCE——
1286BINARY GENOMICS, INC.——
1287ELIXERA, INC.——
1288Distributed Bio, Inc.——
1289PIPA LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.